Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on October 22, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Ying Luo continues as CEO under a new at-will agreement, with $500,000 base salary and $150,000 target 2026 bonus.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Ying Luo continues as CEO under a new at-will agreement, with $500,000 base salary and $150,000 target 2026 bonus
- Thomas Eastling continues as CFO under a new at-will agreement, with $339,066 base salary and $70,000 target 2026 bonus
- Without-Cause or Good-Reason termination triggers six months’ salary, up to twelve months’ COBRA reimbursement, and partial equity acceleration
- Change-of-control termination triggers salary plus target bonus lump sum, up to twelve months’ COBRA reimbursement, and full equity acceleration
- Agreements formalize executive retention and change-of-control protections, potentially increasing transaction-related costs for Gyre
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.